Notice2022-16077
Ivax Pharmaceuticals, Inc.; Withdrawal of Approval of an Abbreviated New Drug Application for Chloramphenicol Capsules, 250 Milligrams
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
July 27, 2022
Issuing agencies
Health and Human Services DepartmentFood and Drug Administration
Abstract
The Food and Drug Administration (FDA) is withdrawing the approval of abbreviated new drug application (ANDA) 062247 for chloramphenicol capsules, 250 milligrams (mg), held by Ivax Pharmaceuticals, Inc. (Ivax). Ivax requested withdrawal of this application and has waived its opportunity for a hearing.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 143 (Wednesday, July 27, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 143 (Wednesday, July 27, 2022)]
[Notices]
[Pages 45109-45110]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-16077]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2022-N-0995]
Ivax Pharmaceuticals, Inc.; Withdrawal of Approval of an
Abbreviated New Drug Application for Chloramphenicol Capsules, 250
Milligrams
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is withdrawing the
approval of abbreviated new drug application (ANDA) 062247 for
chloramphenicol capsules, 250 milligrams (mg), held by Ivax
Pharmaceuticals, Inc. (Ivax). Ivax requested withdrawal of this
application and has waived its opportunity for a hearing.
DATES: Approval is withdrawn as of July 27, 2022.
FOR FURTHER INFORMATION CONTACT: Nikki Mueller, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6280, Silver Spring, MD 20993-0002, 301-
796-3601.
SUPPLEMENTARY INFORMATION: On April 28, 1980, FDA approved ANDA 062247
for chloramphenicol capsules, 250 mg, an antibiotic indicated to treat
only serious infections for which less potentially dangerous drugs are
ineffective or contraindicated. CHLOROMYCETIN (chloramphenicol)
Capsules, 250 mg (ANDA 060591), was the basis of submission for Ivax's
ANDA 062247 for chloramphenicol capsules, 250 mg. In a Federal Register
notice dated July 13, 2012 (77 FR 41412), FDA determined under 21 CFR
314.161 that CHLOROMYCETIN (chloramphenicol) Capsules, 250 mg (ANDA
060591), was withdrawn for safety reasons and that additional
nonclinical and possibly clinical studies of safety and efficacy would
be necessary before CHLOROMYCETIN (chloramphenicol) Capsules, 250 mg,
could be considered for reintroduction to the market. The holders of
approved applications for chloramphenicol capsules, 250 mg, had ceased
marketing of the drug products before July 13, 2012.
On March 29, 2013, Ivax requested that FDA withdraw approval of
ANDA 062247 for chloramphenicol capsules, 250 mg. On June 17, 2021,
Ivax requested that FDA withdraw approval of ANDA 062247 for
chloramphenicol capsules, 250 mg, specifically under Sec. 314.150(d)
(21 CFR 314.150(d)) and waived its opportunity for a hearing. For the
reasons discussed above, and pursuant to the application holder's
request under 314.150(d), approval of ANDA 062247 for chloramphenicol
capsules, 250 mg, and all amendments and supplements thereto, is
withdrawn under Sec. 314.150(d). Distribution of chloramphenicol
capsules, 250 mg, into interstate commerce without an approved
application is illegal and subject to regulatory action (see sections
505(a) and 301(d) of the Federal Food,
[[Page 45110]]
Drug, and Cosmetic Act (21 U.S.C. 355(a) and 331(d))).
Dated: July 20, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-16077 Filed 7-26-22; 8:45 am]
BILLING CODE 4164-01-P
</pre></body>
</html>Indexed from Federal Register on July 27, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.